• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AJRI: American Journal of Reproductive Immunology >Obstetric and perinatal outcome of the women with repeated implantation failures or recurrent pregnancy losses who received pre‐ and post‐conception tacrolimus treatment
【24h】

Obstetric and perinatal outcome of the women with repeated implantation failures or recurrent pregnancy losses who received pre‐ and post‐conception tacrolimus treatment

机译：患有重复植入失败的妇女的产科和围产期结果或接受孕妇后妊娠期治疗后和后孕损失的复发性妊娠损失

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Problem Previously, we reported the clinical efficacy of tacrolimus in women with repeated implantation failures (RIF) of immune etiologies. Safety of tacrolimus in pregnant women has been reported in women with organ transplantations. However, the safety of tacrolimus for women with RIF undergoing assisted reproductive technology cycles and their babies has not been reported prior. Method of study This study is a prospective observational study of 109 women with RIF or recurrent pregnancy losses (RPL) who showed elevated peripheral blood Th1/Th2 (CD4 + IFN‐γ + /CD4 + IL‐4 + ) cell ratios (≥10.3). All received tacrolimus before and during pregnancy (1‐4?mg/d) and delivered a live‐born infant(s). Blood concentrations of tacrolimus were measured. Neuromotor development of the babies was also evaluated. Results Total 113 babies were born from 109 women, including four twin pregnancies. Nine pregnancies including four twins were delivered prematurely (8.3%). Two of 109 women showed obstetric complications, such as hypertensive disorder of pregnancy, and only one baby (0.9%) had a congenital abnormality. There were no differences in babies' birthweight, placental weight, and lymphocyte proportion (%) of the umbilical cord among the women with different tacrolimus dosing. Tacrolimus was detected in the maternal plasma, and its concentration did not significantly fluctuate during pregnancy while on daily administration regimen. Neuromotor development of the babies exposed to tacrolimus in utero was comparable with that of babies from the general population. Conclusion According to our data, tacrolimus treatment for women with RIF and RPL was not associated with obstetrical and perinatal complications. A large size study is needed to confirm this finding.
机译：摘要问题此前，我们报告了他克莫司在患有免疫病因的重复植入失败（RIF）的妇女中的临床疗效。有机体移植的妇女报道了孕妇中的孕妇的立法司安全。然而，尚未报告先前尚未报告接受辅助生殖技术周期及其婴儿的RIF妇女妇女妇女的安全性。该研究该研究是对109名患有RIF或复发性妊娠损失（RPL）的前瞻性观察研究，其显示出升高的外周血TH1 / TH2（CD4 + IFN-γ+ / CD4 + IL-4 +）细胞比率（≥10.3 ）。所有接受妊娠前和怀孕期间（1-4毫克/ d）并交付了一个活生生的婴儿。测量了他克莫司的血液浓度。还评估了婴儿的神经大通发展。结果113名婴儿出生于109名妇女，其中包括四个双胞胎怀孕。九次妊娠，包括四个双胞胎的过早递送（8.3％）。 109名女性中的两种表现出产科并发症，如妊娠高血症紊乱，只有一个婴儿（0.9％）具有先天性异常。婴儿出生重量，胎盘重量和淋巴细胞比例（％）在妇女中患有不同的巨蟹偶给药的妇女中的脐带。在母体血浆中检测到喉蒿，其浓度在每日施用方案时在怀孕期间没有显着波动。暴露于子宫的婴儿的神经大通发展与普通人群的婴儿相当。结论根据我们的数据，RIF和RPL妇女的Tacrolimus治疗与产科和围产期并发症无关。需要大尺寸的研究来确认这一发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号